Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Recurrence × lorlatinib × Clear all

Phase

Phase 1/2 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 9 Non Small Cell Lung Cancer Metastatic 3 Lung Neoplasms 3 Recurrence 1 Neoadjuvant Non-Small Cell Lung Cancer 1 Lymphoma, Large-Cell, Anaplastic 1 Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1 Advanced Non-Small Cell Lung Cancer 1 ALK Positive Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 53 Dexamethasone 40 Rituximab 35 Paclitaxel 25 Lenalidomide 25 Peripheral Blood Stem Cell Transplantation 24 Gemcitabine 23 Etoposide 23 fludarabine phosphate 22 Cytarabine 22 Busulfan 22 Bevacizumab 21 Bortezomib 20 pembrolizumab 19 Radiotherapy 19 Melphalan 18 fludarabine 16 Oxaliplatin 16 Mycophenolic Acid 16 Cisplatin 16 Carboplatin 16 Filgrastim 15 Cyclosporine 15 pomalidomide 14 Antilymphocyte Serum 14 Whole-Body Irradiation 13 Methotrexate 13 Methylprednisolone 12 Bendamustine Hydrochloride 12 Tacrolimus 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03505554 2023-08-07

CRU3

University of Milano Bicocca

Phase 2 Unknown

Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡